DREAMM-2 clinical trial
Not a healthcare professional? Visit our Public site
Not a healthcare professional? Visit our Public site
has been added to your basket
59
For Great Britain (GB) healthcare professionals only - BLENREP is not available in Northern Ireland (NI).
BLENREP has a conditional marketing authorisation.
Learn how fast, deep and durable responses to BLENREP were in a triple-class refractory 5th line plus multiple myeloma (MM) patient population1-3
BLENREP is only available via the private market.
The DREAMM-2 clinical trial studied BLENREP as a single agent in triple-class refractory patients with multiple myeloma (MM) (n=97; final analysis) who had received a median of 7 prior lines of therapy.1
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.2,3
This medicinal product has a conditional marketing authorisation.
DREAMM-2 results at final analysis (40 months follow-up)
The median OS was 15.3 months (95% CI: 9.9-18.9).1
BLENREP delivered a mOS of 30.7 months in patients who achieved a VGPR or better (n=18)
DREAMM-2 results at final analysis (40 months follow-up)
The median DoR was 12.5 months (95% CI; 4.2-19.3)
DREAMM-2 results at final analysis
Median PFS was 2.8 months (95% CI: 1.6-3.6). The estimated mPFS was 14.0 months in patients with a VGPR or better.1
Analysis at 13 month follow up
ORR based on renal function (post-hoc analysis of 13-month follow up)5
Renal function | ORR |
---|---|
Normal renal function (≥90 mL/min/1.73 m2; n=19) |
37% (95% CI: 16.3-61.6) |
Mild renal impairment (≥60–<90 mL/min/1.73 m2; n=48) |
33% (95% CI: 20.4-48.4) |
Moderate renal impairment (≥30–<60 mL/min/1.73 m2; n=24) |
33% (95% CI: 15.6-55.3) |
Prescribing information can be found at the top of this webpage, or here.
BLENREP is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.3
Abbreviations
CI, confidence interval; DoR, duration of response; DREAMM-2, DRiving Excellence in Approaches to Multiple Myeloma 2; eGFR, estimated glomerular filtration rate; GB, Great Britain; HSCT, haematopoietic stem cell transplantation; IgG, immunoglobulin G; ISS, International Staging System; MM, multiple myeloma; MR, minimal response; NI, Northern Ireland; OS, overall survival; ORR, overall response rate; PD, progressive disease; PR, partial response; SD, stable disease; TTBR, time to best response; TTR, time to response; VGPR, very good partial response.
References
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or email us on UKSafety@gsk.com
© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
February 2024 | PM-GB-BLM-WCNT-220003 (V5.0)